Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
Source: sleepreviewmag.com
📰 Test Efficacy News
Test Efficacy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Test Efficacy. Real-time updates on events, politics, business and more.
The NYSPCC Receives $1.65 Million in Grants for Programs that Advance Agency's Mission to Prevent Child Abuse
/PRNewswire/ -- The New York Society for the Prevention of Cruelty to Children (NYSPCC), the worlds first child protection agency, has received $1.65 million...
United States Jacqueline Holloway Jessica Trudeau Domestic Violence Part Of The Supreme Court National Institutes Of Health Human Services For Trauma
Source: prnewswire.com
Myasthenia Gravis Treatment Landscape Rapidly Evolving
Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.
United Kingdom Alexion Myasthenia Gravis Foundation Of America Association Of British Neurologist Association Of British Neurologists British Neurologist Vaccine Clinical Trials
Source: ajmc.com
UCB : Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology Meeting Results presented across...
Source: marketscreener.com
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...
Source: prnewswire.com
UCB : announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Biologic License... | January 6, 2023
Source: marketscreener.com
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine...
Source: prnewswire.com
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
/PRNewswire/ -- UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis...
Source: prnewswire.com
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
UCB, a global biopharmaceutical company, today announced results from two Phase 3 studies evaluating its investigational treatments, zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor) and rozanolixizumab, an SC-infused monoclonal antibody targeting the ...
Source: pharmiweb.com
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com